Ascendiant Capital Markets Issues Pessimistic Forecast for PAVmed (NASDAQ:PAVM) Stock Price

PAVmed (NASDAQ:PAVM) had its target price trimmed by Ascendiant Capital Markets from $19.50 to $19.00 in a research report released on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

PAVmed Trading Up 0.0%

Shares of NASDAQ:PAVM opened at $0.63 on Friday. The stock has a market capitalization of $10.80 million, a PE ratio of -0.15 and a beta of 1.06. PAVmed has a 1 year low of $0.55 and a 1 year high of $1.90. The firm has a fifty day moving average price of $0.68 and a 200 day moving average price of $0.71.

Institutional Investors Weigh In On PAVmed

A hedge fund recently raised its stake in PAVmed stock. First Manhattan CO. LLC. raised its position in shares of PAVmed Inc. (NASDAQ:PAVM) by 16.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 700,000 shares of the company’s stock after acquiring an additional 100,000 shares during the period. First Manhattan CO. LLC. owned approximately 6.32% of PAVmed worth $439,000 as of its most recent SEC filing. 19.93% of the stock is owned by institutional investors and hedge funds.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.